Twist Bioscience (TWST) SVP Dennis Cho Sells $1.3M of Stock

Dennis Cho, Senior Vice President, Chief Legal Officer, and Corporate Secretary at Twist Bioscience Corporation, sold 14,205 shares of the company on June 24, 2026. The shares were sold at an average price of $89.75, totaling approximately $1.27 million. This transaction was part of a pre-planned trading program.

Insider Buying and Selling at Twist Bioscience Corporation

In addition to Dennis Cho's sale, other insiders have also been active. CEO Emily Leproust sold 18,880 shares at $95.00 on June 25, 2026, under a planned program. Earlier, on June 22, 2026, Leproust sold 1,688 shares at $87.32, while Cho sold 346 shares at the same price. Paula Green, SVP of Human Resources, sold 291 shares on June 22, 2026, and had a previous transaction involving 26,137 shares on June 15, 2026, without a specified price.

Twist Bioscience Corporation Stock Down 30.9%

Shares of NasdaqGS:TWST traded near $99.84 on Saturday. Twist Bioscience has a market cap of approximately $6.22 billion and a forward P/E ratio of -130.8, indicating the company is not currently profitable. The stock has experienced a 52-week low of $23.30 and a high of $104.23. Its 50-day moving average is $66.38, and the 200-day moving average is $44.83. The company's beta is 2.214, suggesting higher volatility compared to the market.

Analysts Set New Price Targets

Analysts have been actively reviewing Twist Bioscience. On June 24, 2026, Barclays maintained its 'buy' rating with a price target of $95.00. Earlier in June, TD Cowen and Canaccord Genuity also maintained 'buy' ratings with targets of $89.00 and $90.00 respectively. Piper Sandler initiated coverage with a 'buy' rating and an $85.00 target on June 11, 2026. Overall, the consensus among ten analysts is a strong buy, with a mean price target of $74.10.

About Twist Bioscience

Twist Bioscience Corporation is a healthcare company based in South San Francisco, California. It specializes in manufacturing synthetic DNA-based products for various sectors, including diagnostics, research, and therapeutics. The company is involved in synthetic gene production, offering oligo pools for gene editing and other applications, and provides NGS tools for diagnostic and research purposes. Twist Bioscience was incorporated in 2013 and is led by CEO Dr. Emily Marine Leproust.

Bottom Line

Dennis Cho's recent sale of Twist Bioscience shares is part of a planned transaction, which is common among company insiders. Twist Bioscience continues to be a significant player in the synthetic DNA space, with a substantial market cap and a volatile stock price history. Analyst ratings remain optimistic, with a strong buy consensus highlighting confidence in the company's future prospects.